Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name ERBB3 T355I
Gene Variant Detail

ERBB3 T355I (gain of function)

Relevant Treatment Approaches HER inhibitor (Pan) HER2 Inhibitor HER3 Inhibitor

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB3 T355I estrogen-receptor positive breast cancer sensitive HER2 Inhibitor Fulvestrant + Lapatinib Preclinical - Cell culture Actionable In a preclinical study, the combination therapy of Faslodex (fulvestrant) and Tykerb (lapatinib) resulted in a synergistic effect, demonstrating decreased cell proliferation and reduced colony formation of estrogen-receptor positive breast cancer cells expressing ERBB3 (HER3) T355I in culture (PMID: 29963236). 29963236
ERBB3 T355I estrogen-receptor positive breast cancer no benefit HER2 Inhibitor Lapatinib Preclinical - Cell culture Actionable In a preclinical study, treatment with Tykerb (lapatinib) did not significantly reduce the proliferation of estrogen-receptor positive breast cancer cells expressing ERBB3 (HER3) T355I in culture relative to control and combination treatments (PMID: 29963236). 29963236
ERBB3 T355I estrogen-receptor positive breast cancer no benefit SCH772984 Preclinical - Cell culture Actionable In a preclinical study, treatment with SCH772984 did not significantly reduce the proliferation of estrogen-receptor positive breast cancer cells expressing ERBB3 (HER3) T355I in culture relative to control and combination treatments (PMID: 29963236). 29963236
ERBB3 T355I estrogen-receptor positive breast cancer no benefit HER2 Inhibitor Lapatinib + SCH772984 Preclinical - Cell culture Actionable In a preclinical study, the combination of Tykerb (lapatinib) and SCH772984 resulted in a synergistic effect, demonstrating decreased colony formation and reduced cell proliferation, but to a lesser degree than Tykerb (lapatinib) combined with Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB3 (HER3) T355I in culture (PMID: 29963236). 29963236
ERBB3 T355I estrogen-receptor positive breast cancer no benefit Fulvestrant Preclinical - Cell culture Actionable In a preclinical study, treatment with Faslodex (fulvestrant) did not significantly reduce cell proliferation of estrogen-receptor positive breast cancer cells expressing ERBB3 (HER3) T355I in culture relative to control and combination treatments (PMID: 29963236). 29963236
ERBB3 T355I breast cancer sensitive Patritumab deruxtecan Preclinical - Cell culture Actionable In a preclinical study, Patritumab deruxtecan (U3-1402) treatment inhibited growth of a breast cancer cell line expressing ERBB3 (HER3) T355I in culture (PMID: 35503762). 35503762